TipRanks
Novartis AG (DE:NOT)
XETRA:NOT
Germany Market
NOT
Novartis AG
RESEARCH TOOLSreports

Novartis AG (NOT) Stock News & Sentiment

23 Followers
Nuvectis’ In-Licensed Cancer Drug Earned Breakthrough Designation in China, and It’s Not Even Their Lead Asset
Premium
TipRanks Newswire
Nuvectis’ In-Licensed Cancer Drug Earned Breakthrough Designation in China, and It’s Not Even Their Lead Asset
6d ago
AZN
NVS
Buy Rating Reiterated on Novartis as Diversified Pipeline Supports Medium-Term Growth; CHF 150 Price Target Unchanged
Premium
Ratings
Buy Rating Reiterated on Novartis as Diversified Pipeline Supports Medium-Term Growth; CHF 150 Price Target Unchanged
7d ago
NVS
Novartis Pipeline Strength Outweighs Pelacarsen Setback as Sachin Jain Reiterates Buy and Raises Price Target to CHF 150
Premium
Ratings
Novartis Pipeline Strength Outweighs Pelacarsen Setback as Sachin Jain Reiterates Buy and Raises Price Target to CHF 150
24d ago
NVS
Novartis Maintained at Buy as Strong Remibrutinib Phase 3 Data Support RMS Opportunity; $135 Price Target Unchanged
Premium
Ratings
Novartis Maintained at Buy as Strong Remibrutinib Phase 3 Data Support RMS Opportunity; $135 Price Target Unchanged
30d ago
NVS
Remibrutinib’s Strong Phase III Results and Robust Novartis Pipeline Underpin Unchanged CHF 140 Buy Rating
Premium
Ratings
Remibrutinib’s Strong Phase III Results and Robust Novartis Pipeline Underpin Unchanged CHF 140 Buy Rating
1M ago
NVS
Morgan Stanley’s Graham Parry Reiterates Buy on Novartis, Citing Pelacarsen Upside and Above‑Consensus EPS Outlook
Premium
Ratings
Morgan Stanley’s Graham Parry Reiterates Buy on Novartis, Citing Pelacarsen Upside and Above‑Consensus EPS Outlook
2M ago
NVS
Novartis: Solid Fundamentals but Balanced Risk-Reward Justify Hold Rating
Premium
Ratings
Novartis: Solid Fundamentals but Balanced Risk-Reward Justify Hold Rating
2M ago
NVS
More DE:NOT News >

NOT News on the Web

Goldman Sachs Remains a Sell on Novartis AG (NOVN)
TipRanks News
Neutral
Piper confident Dyne’s Zeleciment rostudirsen will win January FDA approval
TipRanks News
Bearish
HSBC Remains a Buy on Novartis AG (NOVN)
TipRanks News
Neutral
Novartis AG (NOVN) Receives a Hold from UBS
TipRanks News
Neutral
Novartis upgraded to Hold from Reduce at HSBC
TipRanks News
Bearish
Novartis price target lowered to CHF 135 from CHF 142 at Citi
TipRanks News
Bearish
RBC Capital downgrades Novartis AG (NOVN) to a Hold
TipRanks News
Bearish
Novartis initiated with a Sector Perform at RBC Capital
TipRanks News
Bearish

News Score - Last 7 Days

Negative
DE:NOT
Sector Average
Media Buzz
This Week4 articles
Weekly Average17 articles
News Sentiment
This Week0%
Sector Average89%
See how Bullish or Bearish a stock is based on its recent media coverage.

This score is generated using a formula that combines Media Buzz and News Sentiment.

Media Coverage Analysis

The historical news coverage of this asset in the last three months.

FAQ

What is DE:NOT’s Media Buzz Sentiment?
4 articles about DE:NOT were published this week. In an average week, 17 articles are published.
    What is DE:NOT’s weekly average amount of articles?
    In an average week, 17 articles about DE:NOT are published.
      What is DE:NOT’s News Sentiment?
      Currently, no data Available
      General Stocks that are Trending in the News
      RPDRapid7
      TERATera Yatirim Menkul Degerler AS
      R2PD34Rapid7 Inc Shs Unsponsored Brazilian Depositary Receipt Repr 0.083333 Sh
      T2TD34Trade Desk, Inc. Shs A Unsponsored Brazilian Depositary Receipt Repr 0.01 Sh A
      T1AM34Atlassian Corp Shs A Unsponsored Brazilian Depository Receipt Repr 0.05 Sh A
      Showing the stocks with the most bullish news sentiment over the past week